Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 4
2001 3
2002 1
2003 2
2004 3
2005 1
2006 4
2007 1
2008 1
2009 1
2011 3
2012 5
2013 4
2014 4
2015 7
2016 2
2017 2
2018 3
2019 2
2020 2
2021 2
2023 1
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

49 results

Results by year

Filters applied: . Clear all
Page 1
Traditional Cultures versus Next Generation Sequencing for Suspected Orthopedic Infection: Experience Gained from a Reference Centre.
Rimoldi SG, Brioschi D, Curreli D, Salari F, Pagani C, Tamoni A, Longobardi C, Bosari R, Rizzo A, Landonio S, Coen M, Passerini M, Gismondo MR, Gori A, Manzotti A. Rimoldi SG, et al. Among authors: landonio s. Antibiotics (Basel). 2023 Nov 3;12(11):1588. doi: 10.3390/antibiotics12111588. Antibiotics (Basel). 2023. PMID: 37998790 Free PMC article.
Osteonecrosis in protease inhibitor-treated patients.
Bonfanti P, Grabbuti A, Carradori S, Pusterla L, Parrazini F, Landonio S, Quirino T; Italian Coordination for the Study of Allergies and HIV Infection. Bonfanti P, et al. Among authors: landonio s. Orthopedics. 2001 Mar;24(3):271-2. doi: 10.3928/0147-7447-20010301-19. Orthopedics. 2001. PMID: 11300292
Predictors of protease inhibitor-associated adverse events.
Bonfanti P, Ricci E, Landonio S, Valsecchi L, Timillero L, Faggion I, Quirino T; CISAI study group. Italian Coordination for the Study of HIV Infection and Allergies. Bonfanti P, et al. Among authors: landonio s. Biomed Pharmacother. 2001 Jul;55(6):321-3. doi: 10.1016/s0753-3322(01)00070-1. Biomed Pharmacother. 2001. PMID: 11478584 Clinical Trial.
Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimen.
de Salazar A, Dietz J, di Maio VC, Vermehren J, Paolucci S, Müllhaupt B, Coppola N, Cabezas J, Stauber RE, Puoti M, Arenas Ruiz Tapiador JI, Graf C, Aragri M, Jimenez M, Callegaro A, Pascasio Acevedo JM, Macias Rodriguez MA, Rosales Zabal JM, Micheli V, Garcia Del Toro M, Téllez F, García F, Sarrazin C, Ceccherini-Silberstein F; GEHEP-004 cohort, the European HCV Resistance Study Group and the HCV Virology Italian Resistance Network (VIRONET C). de Salazar A, et al. J Antimicrob Chemother. 2020 Nov 1;75(11):3349-3358. doi: 10.1093/jac/dkaa304. J Antimicrob Chemother. 2020. PMID: 32772078
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C.
D'Ambrosio R, Pasulo L, Puoti M, Vinci M, Schiavini M, Lazzaroni S, Soria A, Gatti F, Menzaghi B, Aghemo A, Capelli F, Rumi MG, Morini L, Giorgini A, Pigozzi MG, Rossini A, Maggiolo F, Pan A, Memoli M, Spinelli O, Del Poggio P, Saladino V, Spinetti A, De Bona A, Capretti A, Uberti-Foppa C, Bonfanti P, Terreni N, Menozzi F, Colombo AE, Giglio O, Centenaro R, Borghi M, Baiguera C, Picciotto V, Landonio S, Gori A, Magnani C, Noventa F, Paolucci S, Lampertico P, Fagiuoli S; NAVIGATORE-Lombardia Study Group. D'Ambrosio R, et al. Among authors: landonio s. J Hepatol. 2019 Mar;70(3):379-387. doi: 10.1016/j.jhep.2018.11.011. Epub 2018 Nov 23. J Hepatol. 2019. PMID: 30472321
The effectiveness of desensitization versus rechallenge treatment in HIV-positive patients with previous hypersensitivity to TMP-SMX: a randomized multicentric study. C.I.S.A.I. Group.
Bonfanti P, Pusterla L, Parazzini F, Libanore M, Cagni AE, Franzetti M, Faggion I, Landonio S, Quirino T. Bonfanti P, et al. Among authors: landonio s. Biomed Pharmacother. 2000 Feb;54(1):45-9. doi: 10.1016/s0753-3322(00)88640-0. Biomed Pharmacother. 2000. PMID: 10721462 Free article. Clinical Trial.
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure.
Degasperi E, Spinetti A, Lombardi A, Landonio S, Rossi MC, Pasulo L, Pozzoni P, Giorgini A, Fabris P, Romano A, Lomonaco L, Puoti M, Vinci M, Gatti F, Carolo G, Zoncada A, Bonfanti P, Russo FP, Aghemo A, Soria A, Centenaro R, Maggiolo F, Rovere P, Pasin F, Paon V, Faggiano G, Vario A, Grossi G, Soffredini R, Carriero C, Paolucci S, Noventa F, Alberti A, Lampertico P, Fagiuoli S; NAVIGATORE-Lombardia and Veneto Study Groups. Degasperi E, et al. Among authors: landonio s. J Hepatol. 2019 Dec;71(6):1106-1115. doi: 10.1016/j.jhep.2019.07.020. Epub 2019 Aug 6. J Hepatol. 2019. PMID: 31433303
Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C.
Di Maio VC, Barbaliscia S, Teti E, Fiorentino G, Milana M, Paolucci S, Pollicino T, Morsica G, Starace M, Bruzzone B, Gennari W, Micheli V, Yu La Rosa K, Foroghi L, Calvaruso V, Lenci I, Polilli E, Babudieri S, Aghemo A, Raimondo G, Sarmati L, Coppola N, Pasquazzi C, Baldanti F, Parruti G, Perno CF, Angelico M, Craxì A, Andreoni M, Ceccherini-Silberstein F; HCV Virology Italian Resistance Network Group (Vironet C). Di Maio VC, et al. Liver Int. 2021 Aug;41(8):1802-1814. doi: 10.1111/liv.14797. Epub 2021 Feb 8. Liver Int. 2021. PMID: 33497016
49 results